EPO Patents = 1

Forward Citations = 16

Loading Chart...

4 inventors (with patents filed for the assignee):

Matthew C Mulvey (5 out of 10 patents)

Ian J Mohr (4 out of 13 patents)

Steven R Fuhrmann (1 out of 7 patents)

4. Ram Aiyar (1 out of 1 patent)

5 patents: Sort by Forward Citations

1. 11147846 - Oncolytic herpes simplex virus and therapeutic uses thereof (2021-10-19),

2. 10456432 - Oncolytic herpes simplex virus and therapeutic uses thereof (2019-10-29),

3. 10232003 - Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof (2019-03-19),

4. 10105404 - Oncolytic herpes simplex virus and therapeutic uses thereof (2018-10-23),

5. 9623059 - Oncolytic herpes simplex virus and therapeutic uses thereof (2017-04-18),

Company Overview

Benevir Biopharm, Inc. is a biotechnology company focused on developing novel oncolytic viral therapies for cancer treatment. With a team of researchers and scientists dedicated to advancing the field of immuno-oncology, Benevir is at the forefront of innovative treatments that harness the power of the immune system to target and destroy cancer cells.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

5 Patents

#106 in Rockville, MD

#750 in Maryland

#51,620 in US

Rockville, MD, United States of America

Benevir Biopharm, Inc.

Forward Citations = 16

4 inventors:

Matthew C Mulvey (5 out of 10 patents)

Ian J Mohr (4 out of 13 patents)

Steven R Fuhrmann (1 out of 7 patents)

4. Ram Aiyar (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Benevir Biopharm, Inc.. Retrieved from https://idiyas.com/company/benevir-biopharm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]